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Shiga toxin (STX) is one of the main factors inducing hemorrhagic colitis and hemolytic-uremic 
syndrome (HUS) in infections with STX-producing Escherichia coli (STEC). Approximately 62% of 
patients with HUS showed symptoms of encephalopathy in the 2011 Japanese outbreak of STEC 
infections. At that time, we reported elevated serum concentrations of tumor necrosis factor (TNF)-α 
in patients with acute encephalopathy during the HUS phase. In the current study, we investigated 
whether TNF-α augments the effects of STX in glial cell lines and primary glial cells. We found that 
TNF-α alone or STX in combination with TNF-α activates nuclear factor-κB (NF-κB) signaling and 
inhibits growth of glial cells. The magnitude of the NF-κB activation and the inhibition of cell 
growth by the STX and TNF-α combination was greater than that obtained with TNF-α alone or 
STX alone. Thus, this in vitro study reveals the role of TNF-α in glial cells during STEC infections. 
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1. Introduction 
Shiga toxin (STX), which is produced by some strains of Escherichia coli, causes hemorrhagic 
colitis and hemolytic-uremic syndrome (HUS) [1]. Twenty to fifty percent of HUS cases involve 
central nervous system (CNS) complications that are the most common cause of death in STEC 
infections [1, 2]. However, approximately 62% of patients with HUS showed symptoms of 
encephalopathy in the 2011 Japanese outbreak of infection with STX-producing E. coli (STEC) [3, 
4]. Encephalopathy is a syndrome involving cerebral dysfunction with organic and inorganic causes, 
including cytokine storm and toxic reaction [5, 6]. 
We previously reported that the serum concentration of tumor necrosis factor (TNF)-α was 
higher in patients with acute encephalopathy than in patients without encephalopathy during the 
HUS phase in the 2011 Japanese outbreak of STEC infections [7]. This study suggested that TNF-α 
is a critical factor leading to encephalopathy in STEC infections. 
The brain contains mainly neuronal and glial cells. Glial cells are the most abundant cells 
in the brain and play key roles in cerebral homeostasis, plasticity, and inflammation. Glial cells are 
functional components of the blood-brain barrier (BBB) [8]. Therefore, glial cell hypofunction and 
death impair cerebral homeostasis [9] and are thought to cause CNS complications, including 
encephalopathy [8]. 
In this study, we investigated the effect of TNF-α with or without STX on glial cells in 
vitro. Initially, we studied the effects of TNF-α alone on death of and inflammatory responses in glial 
cells. The subsequent analysis demonstrated that the combination of STX and TNF-α led to greater 
cell death and inflammatory responses than those noted with TNF-α alone in glial cells. Possibly, the 
role of TNF-α in sensitizing glial cells to STX contributes to the development of CNS complications 
in STEC infections. 
 
  
2. Materials and methods 
2.1. Materials 
Dulbecco’s modified Eagle’s medium (DMEM), TNF-α, and Cell Counting Kit 8 were obtained 
from Wako Pure Chemical Industries, Ltd (Osaka, Japan). Shiga toxin-2 (STX) was obtained from 
Nacalai Tesque (Kyoto, Japan). Fetal bovine serum (FBS) was obtained from Invitrogen Corporation 
(Carlsbad, CA, USA). Anti-phospho-specific nuclear factor-κB (NF-κB) p65 (Ser536), 
anti-phospho-specific c-Jun N-terminal kinase (JNK; Thr183/Tyr185), anti-phospho-specific p38 
mitogen-activated protein kinase (MAPK; Thr180/Tyr182), anti-β-actin, and 
horseradish-peroxidase-conjugated anti-rabbit IgG antibodies were purchased from Cell Signaling 
Technology (Danvers, MA, USA). 
 
2.2. Cell culture 
B92 rat cells [10] and primary rat glial cells [11] were gifted by Dr. Ohno-Shosaku (Kanazawa 
University, Japan). The glial fibrillary acidic protein, a marker of astrocyte, was expressed in 
primary cells that Dr. Ohno-shosaku provided, indicating astrocytes [9]. The cells were maintained 
in DMEM containing 10% FBS at 37°C in a 5% CO2 incubator. Subcultures were required to 
maintain that both cells were in the logarithmic phase of growth during culture. 
 
2.3. Cell proliferation assay 
Cell proliferation was analyzed using Cell Counting Kit 8. B92 rat glial cells and primary glial cells 
were seeded in 96 well-plates at a density of 3 × 10³ cells/well. After 24-h incubation, the cells were 
then treated with TNF-α and/or STX2 for 48 h. Next, the cells were incubated with 10 µl WST-8 for 
2 h. The absorbance of the colored formazan product produced by mitochondrial dehydrogenases in 
metabolically active cells was recorded at 450 nm as the background value. Cell proliferation was 
expressed as a percentage of absorbance obtained in treated wells relative to that in untreated 
(control) wells. 
 
2.4. Western blotting  
Western blotting was performed as described previously [12, 13]. 
 
2.5. Statistical analysis  
Data are presented as the mean ± SEM from at least three independent experiments. Statistical 
analysis was conducted using a Kruskal Wallis non-parametric ANOVA followed by a Bonferroni 




3.1. TNF-α-induces downregulation of cell growth and upregulation of NF-κB activity in B92 glial 
cells 
 
First, we examined the effects of TNF-α on growth of cultured glial cells. TNF-α (50–500 ng/mL) 
considerably inhibited cell growth (Fig. 1A) and cleaved caspase-3 (Suppl. Fig. 1) in a 
concentration-dependent manner in B92 glial cells. 
Next, we examined the effects of TNF-α on inflammation in cultured glial cells. TNF-α 
(5–500 ng/mL) significantly phosphorylated NF-κB in a concentration-dependent manner in B92 
glial cells (Fig.1B), indicating TNF-α induced activation of NF-κB signaling. 
 
3.2. STX facilitates TNF-α-induced downregulation of cell growth and TNF-α-induced upregulation 
of NF-κB activity in B92 glial cells 
 
Our previous study showed that STX (0.03–3 ng/mL) did not inhibit growth of B92 glial cells [14]. 
Likewise, in the current study, STX (3 ng/mL) alone failed to alter growth of B92 glial cells; 
however, it significantly facilitated TNF-α-induced downregulation of growth of these cells 
(Fig.2A). 
Although STX alone failed to phosphorylate NF-κB, it facilitated TNF-α-induced NF-κB 
phosphorylation in B92 glial cells (Fig.2B). 
 
3.3. STX facilitates TNF-α-induced activation of JNK and p38 MAPK in B92 glial cells 
 
STX alone phosphorylated JNK but not p38 MAPK in B92 glial cells, indicating that it activates 
JNK but not p38 MAPK (Fig.3). In contrast, TNF-α alone phosphorylated both JNK and p38 MAPK 
in B92 glial cells, indicating that it activates both JNK and p38 MAPK (Fig.3). The combination of 
STX and TNF-α strongly phosphorylated both JNK and p38 MAPK in glial cells. STX significantly 
facilitated TNF-α-mediated phosphorylation of JNK (Fig.3). 
 
3.4. STX facilitates TNF-α-induced upregulation of NF-κB activity in primary glial cells 
 
TNF-α, but not STX, phosphorylated NF-κB in primary B92glial cells (Fig.4). Although STX alone 
failed to activate NF-κB, it significantly facilitated TNF-α-induced NF-κB phosphorylation, 
indicating the activation of NF-κB (Fig.4). 
 
3.5. STX facilitates TNF-α-induced activation of JNK and p38 MAPK in primary glial cells 
 TNF-α, but not STX, phosphorylated both JNK and p38 MAPK in primary glial cells (Fig.5). STX 
alone failed to activate JNK or p38 MAPK, similar to its effect on NF-κB activity. However, STX 




In the current study, we demonstrated that TNF-α inhibits cell growth and activates NF-κB, JNK, 
and p38 MAPK in a concentration-dependent manner in glial cells. STX combined with TNF-α 
decreased cell growth and activated NF-κB, JNK, and p38 MAPK to a greater extent than STX alone 
or TNF-α alone. These results suggest that TNF-α modifies disease progression in STEC infections. 
STEC and STX cause hemorrhagic diarrhea and the potentially lethal HUS in severe cases 
[1]. HUS in STEC infections often involves neurological symptoms and signs of encephalopathy [1, 
2]. The neurological symptoms and signs of encephalopathy include seizures, alteration of 
consciousness, focal neurological deficits, visual disturbances, and brainstem symptoms. 
Neurological manifestations are associated with increased mortality. 
STEC are gram-negative bacilli that have lipopolysaccharide (LPS) in their cell walls [15]. 
LPS acts as an endotoxin, stimulates macrophages, and causes release of cytokines from 
macrophages, including TNF-α [16]. TNF-α is a master cytokine that mediates the inflammatory 
response and innate immunity [17]. TNF-α causes cell death and elicits stress responses, including 
JNK and p38 MAPK signaling [17]. In our previous study, we showed that the serum concentration 
of TNF-α in patients with acute encephalopathy was higher than that in patients without 
encephalopathy in the 2011 Japanese outbreak of STEC infections, suggesting that TNF-α is a 
critical cytokine in relation to the development of encephalopathy [7]. In this study, TNF-α induced 
death (Fig.1) of and NF-κB, JNK, and p38 MAPK activation (Fig.3, 5) in glial cells, indicating that 
TNF-α might modify glial cell conditions. 
However, the role of STX in the mechanism underlying encephalopathy is still unclear. 
Glial cells are the most abundant cells in the brain and are functional components of the BBB [8]. 
Thus, glial cells play key roles in cerebral homeostasis, plasticity, and inflammation. When the glial 
cells are dead or show abnormally low function, cerebral homeostasis might be disrupted. In our 
present in vitro study, the combination of STX and TNF-α caused much greater damage to glial cells 
than TNF-α alone or STX alone (Fig.2-5). STX is multifunctional protein inducing protein 
biosynthesis inhibition and endoplasmic reticulum (ER) stress response [18]. ER stress is widely 
reported to induce apoptotic cell death [19]. Thus, STX may enhance TNF-α induced cell death. 
These results indicate that STX, together with TNF-α, likely causes glial cell death and disrupts 
cerebral homeostasis, resulting in brain damage (including encephalopathy). 
Indeed, STX and TNF-α have been found in the blood of STEC patients with 
encephalopathy [7]. When STX and TNF-α reach the brain, STX, TNF-α, or both attack the vascular 
endothelial cell layer that forms the anatomical BBB and disrupt the endothelial layer [20, 21]. In 
turn, TNF-α or the combination of STX and TNF-α affect glial cells that play roles in the functional 
BBB and homeostasis, and induce their death. Encephalopathy is recognized as a major determinant 
of mortality during the acute phase of STEC infections. Although the pathogenesis of CNS 
complications is unclear, BBB disruption and neuronal disturbances are observed during the acute 
phase of STEC infections [22-24]. The overall result of these events is likely to be encephalopathy in 
STEC patients. 
 
5. Conclusions  
The current study showed that TNF-α potentiated glial cell death and inflammation induced by STX 
treatment. Glial cells play key roles in cerebral homeostasis, plasticity, and inflammation; thus, these 
results suggest that TNF-α is a critical factor in relation to the development of encephalopathy in 
STEC infections. 
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Fig.1. TNF-α induces decrease in cell proliferation and increase in phosphorylation of NF-κB in B92 
glial cells. (A) The effects of TNF-α on cell growth at 48 h after treatment. (B) The effects of TNF-α 
on phosphorylation of NF-κB at 30 min after treatment. Data is representative of at least three 
independent experiments. Each column represents the mean ± SEM. ∗∗P < 0.01 versus vehicle 
control (0 ng/mL). 
 
Fig.2. The combination of STX and TNF-α induces decrease in cell proliferation and increase in 
phosphorylation of NF-κB in B92 glial cells. (A) The effects of STX and/or TNF-α on cell growth at 
48 h after treatment. (B) The effects of STX and/or TNF-α on phosphorylation of NF-κB at 30 min 
after treatment. Data is representative of at least three independent experiments. Each column 
represents the mean ± SEM. ∗P < 0.05 or ∗∗P < 0.01 versus vehicle control, !!P < 0.01 versus STX 
alone, ##P < 0.01 versus TNF-α alone. 
 
Fig.3. The combination of STX and TNF-α increases phosphorylation of JNK and p38 in B92 glial 
cells. The effects of STX and/or TNF-α on phosphorylation of JNK at 30 min after treatment. The 
effects of STX and/or TNF-α on phosphorylation of p38 at 30 min after treatment. Data is 
representative of at least three independent experiments. Each column represents the mean ± SEM. 
∗P < 0.05 or ∗∗P < 0.01 versus vehicle control, !!P < 0.01 versus STX alone, ##P < 0.01 versus TNF-α 
alone. 
 
Fig.4. The combination of STX and TNF-α increases phosphorylation of NF-κB in primary glial 
cells. The effects of STX and/or TNF-α on phosphorylation of NF-κB at 30 min after treatment. Data 
is representative of at least three independent experiments. Each column represents the mean ± SEM. 
∗∗P < 0.01 versus vehicle control, !!P < 0.01 versus STX alone, ##P < 0.01 versus TNF-α alone. 
 
Fig.5. The combination of STX and TNF-α increases phosphorylation of JNK and p38 in primary 
glial cells. The effects of STX and/or TNF-α on phosphorylation of JNK at 30 min after treatment. 
The effects of STX and/or TNF-α on phosphorylation of p38 at 30 min after treatment. Data is 
representative of at least three independent experiments. Each column represents the mean ± SEM. 
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